Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
OncoC4, Inc.
Aulos Bioscience, Inc.
Memorial Sloan Kettering Cancer Center
Sotio Biotech Inc.
Pfizer
M.D. Anderson Cancer Center
ViroMissile, Inc.
Tizona Therapeutics, Inc
Essen Biotech
Azienda Ospedaliero-Universitaria di Parma
Jonsson Comprehensive Cancer Center
MacroGenics
City of Hope Medical Center
Daiichi Sankyo
Second Life Therapeutics
Ocellaris Pharma, Inc.
OncoNano Medicine, Inc.
Mayo Clinic
University of Pittsburgh
University Health Network, Toronto
Cancer Research UK
NeoTX Therapeutics Ltd.
UNC Lineberger Comprehensive Cancer Center
Actym Therapeutics, Inc.
University of Arizona
Institut Bergonié
Day One Biopharmaceuticals, Inc.
Washington University School of Medicine
Palleon Pharmaceuticals, Inc.
Sensei Biotherapeutics, Inc.
Cancer Research UK
Toray Industries, Inc
Memorial Sloan Kettering Cancer Center
Medicenna Therapeutics, Inc.
Marengo Therapeutics, Inc.
Genentech, Inc.
NGM Biopharmaceuticals, Inc
Revolution Medicines, Inc.
Seagen Inc.
National Cancer Institute (NCI)
Stanford University
European Organisation for Research and Treatment of Cancer - EORTC
Pfizer
Xencor, Inc.
ADC Therapeutics S.A.
Arcus Biosciences, Inc.
Cedars-Sinai Medical Center
Pfizer
Adaptimmune